Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of ProQuad rHA in Children 9 to 12 Months of Age
NCT00566527Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2007
- Primary completion
- Dec 2008
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 3, randomised, open-label trial of varicella virus vaccine live in measles, mumps, rubella and 1 more (3 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants in Arm 2 and Arm 3 Meeting Antibody Immunogenicity Response Criteria Following ProQuad Dose 2 at Day 132, Percentage of Participants in Arm 1 and Arm 3 Meeting Antibody Immunogenicity Response Criteria Following ProQuad Dose 2 at Day 132 and 4 more. Started Nov 2007; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
measlesmumpsrubellavaricella (VZV)
Beyond the preview
Go deeper on NCT00566527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00566527.